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Summary
Objective: Osteoarthritis (OA) is prevalent and difﬁcult to treat. Autologous conditioned serum (ACS), marketed under the trade name Ortho-
kine, is a novel, injectable antiarthritic derived from the patient’s own blood. The present study is the ﬁrst time ACS has undergone a controlled
clinical trial.
Method: We investigated 376 patients with knee OA in a prospective, randomized, patient- and observer-blinded, placebo-controlled trial using
an intention-to-treat analysis (ITT). The clinical effects of ACS were compared to hyaluronan (HA) and saline (placebo) as assessed by
patient-administered outcome instruments (Western Ontario and McMaster Universities osteoarthritis index, global patient assessment, visual
analog scale, Short-Form 8) after 7, 13 and 26 weeks. After 104 weeks an observer-blinded follow-up was carried out. Frequency and severity
of adverse events were used as safety parameters.
Results: In all treatment groups, intra-articular injections produced a reduction in symptoms as well as an improvement in quality of life. How-
ever, the effects of ACS were signiﬁcantly superior to those of HA and saline for all outcome measures and time points, and improvements
were clinically relevant; there were no differences between the effects of HA and saline. The frequency of adverse events was comparable in
the ACS and saline groups, but higher in the HA group.
Conclusion: The data demonstrate that ACS injection considerably improves clinical signs and symptoms of OA. It remains to be determined
whether ACS is disease-modifying, chondroprotective, or chondroregenerative.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the single most important cause of
locomotor disability in Western societies and a major bur-
den on their healthcare systems1,2. It is a progressive,
chronic condition leading to pain and loss of function
that dramatically reduces patients’ quality of life and abil-
ity to work. Pharmacologic treatment options for OA are
very limited3e7. They include analgesics, non-steroidal
anti-inﬂammatory drugs (NSAIDs), and the intra-articular
injection of steroids or hyaluronan (HA). Intra-articular
HA is commonly used as a safe, off-the-shelf, treatment
for OA of the knee, but its efﬁcacy is controversial. There
is a pressing need for novel, improved, mechanism-based
agents for treating OA.
OA is accompanied by a number of mechanical and
biologic dysfunctions within the joint, the central pathologic
feature being the destruction of hyaline cartilage. Of the cat-
abolic cytokines identiﬁed in osteoarthritic joints, interleukin-
1 (IL-1), the most potent known mediator of cartilage*Address correspondence and reprint requests to: Carsten
Moser, M.D., Centre for Molecular Orthopaedics, Koenigsallee
53-55, D-40212 Du¨sseldorf, Germany. Tel: 49-173-3771731; Fax:
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152loss8e17, appears pivotal. The naturally occurring inhibitor
of IL-1, the IL-1 receptor antagonist (IL-1Ra), could poten-
tially limit the intra-articular actions of IL-118e20 and thereby
control the disease process. Several investigators have
reported effectiveness of IL-1Ra when delivered by intra-
articular injection in a canine model of OA and in a pilot
human study21, or when delivered by intra-articular gene
transfer22,23 in dogs24, rabbits25, and horses26.
Autologous conditioned serum (ACS) was developed in
the mid-1990s in an attempt to generate an injectable
material enriched in endogenous IL-1Ra as a novel thera-
peutic for OA. Meijer et al.27 noted that exposure of blood
to glass beads elicits a vigorous, rapid increase in the
synthesis of several anti-inﬂammatory cytokines, including
IL-1Ra. This observation is the basis for producing ACS,
which is injected into the affected joint in a series of six in-
tra-articular injections given twice a week for 3 weeks. This
therapy is currently available for humans in several Euro-
pean countries and its use is even more widespread for
equine OA, where ACS considerably improves clinical
lameness in horses and may protect cartilage from degra-
dation28. Preliminary data from a large non-blinded patient
observational study in humans29 provided encouragement
for the present trial, which was designed to test the
hypothesis that ACS is superior to saline and HA as an
intra-articular therapy for reducing the signs and symptoms
of knee OA.
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This study was based on a 26-week prospective, randomized, controlled,
parallel-group design trial. During the ﬁrst 6 months of the initial randomized
controlled trial (RCT), both patients and observer were blinded (masked
observer).
Patients with primary OA of the knee were recruited from ﬁve orthopedic
centers between October 2003 and July 2004 (consolidated statement of
reporting trials (CONSORT) ﬂow chart, Fig. 1). Participants had to be older
than 30 and willing to discontinue all analgesics and NSAIDs for at least 6
months. Participants had to have had OA for at least 3 months at the time
of inclusion, as assessed by American College of Rheumatology criteria30,
KellgreneLawrence grade 2e3 radiographic evidence of knee OA31, and a vi-
sual analog scale (VAS) pain rating of at least 50 on a 100-mm scale at the
time of inclusion. Previous surgery of the studied knee was acceptable, pro-
vided it preceded the start of injections by at least 3 months. Exclusion crite-
ria were grade IV OA, systemic or inﬂammatory joint diseases, a history of
crystalline arthropathy or neuropathic arthropathy, clinically relevant hemato-
logic or abnormal clinical chemistry values, bone cancer, and metastasis or
tumor-like lesions in immediate proximity to the treated joint. Patients were
also excluded if they were pregnant or lactating, abused drugs (alcohol, an-
algesics, and opiates), had received an intra-articular injection of any of the
trial substances within the previous 6 months, or had a known allergy or hy-
persensitivity to any of the trial substances. KellgreneLawrence scores were
assessed on the basis of X-rays (conventional standing anteroposterior ra-
diograph) up to 1 year old. Patients with a score of 2 or 3 on entry were el-
igible. Joint space width was not measured, as literature indicates that
changes may only be apparent radiographically in longer studies of 18e24376 patients underwent randomiza
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Fig. 1. Patient disposition. Flow chart showinmonths duration. The 6-month follow-up period of the current trial was there-
fore too short to reasonably expect protective effects to be detected in knee
radiographs32e34.
Subsequently, all volunteers were seen by one specially trained study
physician (blinded observer) at the study center, who provided information
concerning the trial, products, alternatives and risks, and obtained written in-
formed consent. Next, the volunteers completed all baseline questionnaires.
After application of inclusion and exclusion criteria, a total of 376 patients
(safety population analysis) were enrolled. Participants were allocated to
one of the three groups (ACS, HA or saline) on the basis of a randomization
list, by individuals at the blood-processing site who were not otherwise in-
volved in the trial.
All patients had 50 mL of whole blood taken using a special syringe with
increased inner surface area (Orthogen, Du¨sseldorf, Germany). Samples
from patients receiving saline or HA injections were discarded. Medical-
grade glass beads in the special syringes increase the nonpyrogenic surface
area. These glass spheres induce the dose-dependent production of IL-1Ra
by white blood cells in whole blood incubated at 37C. After incubation, the
blood-ﬁlled syringes were centrifuged, and the serum supernatant was ﬁl-
tered (0.22 mm; Millipore, Carrigtwohill, Co. Cork, Ireland) and aliquoted
into 6e8 2 mL portions. The aliquots were frozen at 20C and tested for hu-
man immunedeﬁciency virus (HIV), syphilis, hepatitis B and C before being
released for injection.
All participants had two appointments with a physician per week for three
consecutive weeks. Subjects in the placebo group received one injection per
week of saline. Subjects in the HA group received one injection per week of
a 1% solution of HA with a molecular weight of 1.4 106 D (HYA-Ject,
Ormed, Freiburg, Germany). The injections consisted of 2 mL of HAtion and received at least
 treatment (ACS or HA or saline)
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Table I
Baseline demographics and baseline disease characteristics of
study subjects
Parameter ACS HA Saline
Number of patient knees 134 135 107
Average age (year) 53.8 12.2 57.4 12.0 60.3 10.7
Gender (f/m) 65/69 74/61 68/39
Previous knee surgery (%) 59.4 58.7 60.2
WOMAC pain (mean) 5.2 2.4 4.9 2.1 4.9 2.0
WOMAC stiffness (mean) 5.6 2.8 6.0 2.7 5.8 2.8
WOMAC function (mean) 5.2 2.4 5.2 2.1 5.2 2.2
Global WOMAC (mean) 5.2 2.3 5.2 2.0 5.2 2.1
VAS (mm) 69.6 13.1 68.3 12.8 66.3 14.5
SF-8 PCS 29.4 6.7 28.7 5.7 29.5 5.8
SF-8 MCS 42.6 11.7 43.3 12.1 43.8 12.4
WOMAC osteoarthritis index (mean scores on each subscale and
global WOMAC; range 0e10). VAS e weight-bearing pain (range
0e100 mm). SF-8¼Medical Outcomes Study Short-Form 8 Health
Survey (range 0e100). Pluseminus values are meanSD.
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jects in the saline and HA groups received an application of topical heparin-
natrium cream at the second appointment every week. This was done so that
all patients would have six appointments with a treating physician. Subjects
receiving ACS also had six appointments but received an injection of ACS at
each appointment. In all cases, a sterile 21-gauge needle was inserted an-
tero-laterally into the joint under aseptic conditions and synovial ﬂuid present
was aspirated to minimize drug dilution. The needle was left in place and
2 mL of the respective study medication was injected. The procedures
were identical for each group and were performed without any concurrent
medication or use of local anesthesia. For technical reasons (e.g., differ-
ences in viscosity, color) blinding of the doctor administering the medication
was not possible.
To evaluate pain severity, analgesic and anti-inﬂammatory medications
were discontinued before the start of treatment. The washout period was 3
weeks, starting from the day of inclusion until the ﬁrst injection. ACS was pro-
duced for patients in the ACS group, and all patients were scheduled for ther-
apy. Patients were permitted to use paracetamol (acetaminophen)35,36, up to
4 g/day, as a rescue medication. NSAIDs were not permitted throughout the
trial.
In all, 376 patients underwent randomization and received at least one in-
tra-articular injection of the assigned treatment. Total study duration was 32
weeks for patients receiving all injections, or 29 weeks for patients who re-
ceived only one injection. Six weeks, 3 months and 6 months after the last
trial injection, patients were recalled to the study center and completed the
same questionnaires as they had at baseline prior to being seen by the
blinded observer.
Twenty-one patients also received injections of the study medications in
the contralateral knee 3e6 months after the ﬁrst knee. The second knees
were evaluated separately and the data were not included in our analyses.
In each of these cases the more painful knee was treated ﬁrst, and only
data from the ﬁrst knee were included in the study. Two patients (one ACS
and one HA) were excluded from statistical analysis after exclusion criteria
became apparent during the injection period. Treatment failures due to ag-
gravation of symptoms and dropouts (lost to follow-up) were equally distrib-
uted between the three treatment groups (Fig. 1).
Patients requiring additional treatment during the trial were documented
and were regarded as clinically failing or withdrawing from treatment. Clinical
failure was deﬁned as the use of concurrent treatment for the study knee,
e.g., analgesics (more than 4 g acetaminophen per day), surgery, NSAIDs
(on prescription), or additional injections. Patients who elected to withdraw
from the trial were considered treatment failures but were still followed for
6 months to monitor possible late adverse reactions.
Baseline characteristics were recorded before the ﬁrst injection. Patients
rated their subjective status using a 100-mm VAS. The patient-administered
Western Ontario and McMaster Universities (WOMAC) osteoarthritis instru-
ment, the Short-Form 8 health-related quality of life (SF-8 HRQL) survey,
and the global patient assessment (GPA) of treatment efﬁcacy were per-
formed at baseline and at weeks 7, 13 and 26.
The WOMAC index is a disease-speciﬁc quality-of-life instrument devel-
oped for assessing patients with OA. It comprises three dimensions: pain,
stiffness, and physical function. It is both reliable and valid37,38. Scores
were calculated as an average for each subscale (0e10 scale, with higher
scores indicating worse condition).
The 100-mm VAS (0¼ no pain; 100¼worst possible pain) has been val-
idated and is comparable to other methods. It has adequate sensitivity and
statistical power for data collection39,40. The overall question was ‘‘How
much pain did you have due to your knee joint in the past week?’’ A
VAS> 50 mm is a stricter inclusion criteria than has been used in some other
studies41e44, but our objective was to treat painful OA cases.
It may be that including only patients with VAS> 50 mm resulted in a re-
markably low standard deviation (SD) seen for VAS at baseline (perhaps in
part as a result of primary care physicians knowing the inclusion criteria
thresholds) and in bias toward more aggressive and more inﬂammatory man-
ifestations of OA.
The SF-8 HRQL is a self-administered questionnaire comprising eight di-
mensions. Single-item scores, physical component score (PCS) and mental
component score (MCS) were calculated, with higher scores representing
better HRQL45e47.
In addition to the treatment outcome measures, patients’ satisfaction with
treatment efﬁcacy was assessed by GPA48. Each patient was asked ‘‘How
would you rate the effectiveness of your osteoarthritis treatment right
now?’’ Clinically meaningful satisfaction was deﬁned as a grade of 1e3 on
a six-point scale with lower grades representing better outcomes.
Baseline demographics and baseline disease characteristics (Table I)
were statistically identical in the three groups, except for age differences be-
tween ACS and HA and between ACS and saline (P< 0.05). Subsequent
stratiﬁcation and correlation analysis showed no signiﬁcant correlations be-
tween baseline demographic characteristics (gender, previous knee surgery
or laboratory test results) and treatment outcome. In addition, sub-analysis
for age (age groups determined using quartiles and median of age distribu-
tion were 30e48, 49e59, 60e66 and 67e84 years) did not show signiﬁcant
differences in responsiveness between these subgroups (e.g., WOMAC:pain P¼ 0.9827, stiffness P¼ 0.7207, function P¼ 0.8995, global
P¼ 0.9011, VAS: P¼ 0.8364).
The trial protocol was designed to detect a change of 20% in the WOMAC
score between ACS and HA, and between HA and saline, with a two-sided
level of signiﬁcance of 5%49. The calculation of the number of patients was
performed with nQuery Advisor version 4.0 (Statistical Solutions, Saugus,
MA, USA). With an expected SD of 40% (WOMAC score), as frequently
found in other OA treatment trials, and taking into account that there would
be a dropout rate of approximately 25%, 108 patients per group were re-
quired for a power of >80%. Descriptive statistics were calculated by treat-
ment group and time point, using the last observation carried forward
(LOCF) method of imputation. At baseline, homogeneity of demographic
and disease characteristics was tested with an analysis of variance one-
way method for continued parameter and a chisquare test for categorical pa-
rameter. A general linear model for repeated measurement was used to com-
pare the longitudinal proﬁle of the groups, and a multiple comparison
between the groups was performed. Changes from baseline and compari-
sons of groups for all scores were calculated using an analysis of variance
one-way test. Results are presented graphically, using the mean proﬁle
per group, and analytically, reporting the P values for each contrast. Statis-
tical analysis was performed using SAS for Windows (SAS Institute, Cary,
NC, USA) on a personal computer.
Intention-to-treat analysis was performed for the outcome of primary and
secondary variables, and a safety analysis was performed including all
patients who received at least one intra-articular injection.
Adverse events were used to compare the safety proﬁle of the three
groups. At each study visit, adverse events experienced since the previous
visit were evaluated. Each event was recorded, along with whether the event
was localized to the injected knee or general (systemic) in nature, its dura-
tion, and what, if any, measures or treatment were required. Adverse events
localized to the injected knee were deﬁned as pain, swelling, or effusion and
were reported as such, even though these can also be symptoms of OA.TWO-YEAR FOLLOW-UPPatients who completed the 6 months of the trial without any major proto-
col violations (per-protocol population) were recalled to the study center and
followed up prospectively 2 years after the last trial injection in an observa-
tional, prospective, cohort study with a new blinded observer. This follow-
up evaluation was conducted to determine whether therapeutic effects
were still present after 2 years and which patients subsequently needed con-
comitant medication or additional therapy.Results
ACS (Orthokine) resulted in signiﬁcantly greater improve-
ment over time than did the control treatments. Furthermore,
patients treated with ACS consistently showed signiﬁcantly
higher relative improvements compared to the control
groups for all outcome parameters (Tables II and IV).
WOMAC subscale scores were reduced in all treatment
groups, with the largest reduction occurring in the ACS
group (Table II). The ACS group scored signiﬁcantly better
Table II
Outcome scores per treatment group over time
WOMACGlobal WOMACPain WOMACStiffness WOMACFunction
Mean SD Mean SD Mean SD Mean SD
ACS (N¼ 134)
Baseline 5.24 2.32 5.18 2.39 5.59 2.7 5.21 2.41
Week 7 2.80 2.30 2.71 2.37 3.07 2.49 2.80 2.34
Week 13 2.42 2.06 2.33 2.14 2.80 2.33 2.40 2.08
Week 26 2.42 2.19 2.42 2.25 2.78 2.45 2.37 2.21
HA (N¼ 135)
Baseline 5.19 2.04 4.89 2.12 6.04 2.65 5.17 2.11
Week 7 4.02 2.09 3.63 2.09 4.82 2.65 4.04 2.14
Week 13 4.00 2.17 3.73 2.22 4.75 2.68 4.00 2.19
Week 26 3.75 2.42 3.59 2.47 4.32 2.78 3.74 2.44
Saline (N¼ 107)
Baseline 5.16 2.12 4.86 2.01 5.78 2.77 5.18 2.24
Week 7 3.81 2.33 3.49 2.23 4.45 2.89 3.83 2.42
Week 13 3.99 2.13 3.61 2.11 4.69 2.78 4.01 2.20
Week 26 3.93 2.38 3.68 2.24 4.51 2.82 3.94 2.48
VAS PCS (SF-8) MCS (SF-8)
Mean SD Mean SD Mean SD
ACS (N¼ 134)
Baseline 69.6 13.10 29.39 6.65 42.60 11.74
Week 7 33.8 23.92 40.21 9.96 49.96 10.48
Week 13 29.6 23.14 42.87 9.46 51.09 9.22
Week 26 29.5 22.58 41.62 10.12 50.66 10.68
HA (N¼135)
Baseline 68.3 12.81 28.65 5.65 43.25 12.10
Week 7 52.6 23.15 34.57 9.07 46.50 12.46
Week 13 52.1 22.97 34.66 9.42 46.43 11.19
Week 26 49.3 25.90 35.62 10.10 46.51 11.48
Saline (N¼107)
Baseline 66.3 14.49 29.45 5.84 43.79 12.38
Week 7 46.7 23.52 35.60 9.12 47.26 11.08
Week 13 48.8 22.51 34.52 8.59 45.69 10.61
Week 26 48.2 25.59 34.99 8.96 46.22 11.07
Note that ACS-treated patients scored signiﬁcantly better than those treated with HA and saline at all data points, whereas there are no
signiﬁcant differences at any data point between HA and saline.
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points after the injections (P< 0.001 for each comparison).
No differences were observed between HA and saline in
any of the WOMAC scores across time (each P> 0.05 for
the comparison HA vs saline).
VAS ratings at weeks 7, 13, and 26 were lowest in the
ACS group (P< 0.001 for all comparisons with either HA
or saline at all time points). After ACS injections, the
mean pain rating decreased from 69.6 mm to 29.6 mm at
week 13 and to 29.5 mm at week 26 (Table II). ACS treat-
ment produced a higher number of patients who experi-
enced more than 50% improvement as assessed by VAS
at all time points (VAS response [>50% improvement] at
week 26: ACS 67%, HA 32%, saline 33%; each
P< 0.001). GPA scores at all of the follow-up visits were
higher (each P< 0.001) with ACS than with either HA or
saline (Table III).
In all SF-8 HRQL dimensions and component scores,
ACS treatment was associated with the largest improve-
ment (P< 0.001 for each comparison). In particular, the
SF-8 PCS and MCS were higher (P< 0.001 in both cases)
after ACS treatment than in either control group (Table II).
Only local adverse events (Table V) occurred in all
groups, with one exception (in the HA group). We observedno infections. Five patients in the HA group (3.7%) and two
patients in the saline group (2%) withdrew because acute
local reactions developed after an injection. Of the ﬁve pa-
tients in the HA group, four required treatment with synovial
aspiration and intra-articular administration of a corticoste-
roid (triamcinolone). Clear yellow ﬂuids were aspirated.
Cell counts revealed inﬂamed states. There were no crys-
tals. Gram stain and microbial cultures were negative.
These patients received NSAIDs, ice packs, and rest. Their
symptoms improved within a couple of days. One patient re-
ceiving HA had a generalized skin reaction (allergy) after
the second injection and discontinued the trial medication.
In the ACS group, mild and moderate symptoms were ob-
served directly after the intra-articular injections. These
symptoms (pain or pressure sensation) improved within
minutes or within 24 h after injection at most. None of the
reactions in the ACS group needed further intervention.
There were no differences in the three treatment groups
with respect to use of concomitant medication or number
of medications used, and no correlation between use of
medication and treatment outcome. Numbers with bilateral
therapy were too small to provide useful information. How-
ever, we cannot exclude completely that there may have
been a contralateral effect, too.
Table III
GPA of treatment efficacy
Treatment group GPA values
1 2 3 4 5 6
ACS Week 13 29 (22%) 45 (34%) 26 (20%) 12 (9%) 16 (12%) 3 (2%)
Week 26 32 (24%) 36 (27%) 24 (18%) 20 (15%) 15 (11%) 4 (3%)
HA Week 13 3 (2%) 22 (18%) 27 (22%) 25 (20%) 38 (31%) 9 (7%)
Week 26 9 (7%) 21 (17%) 20 (16%) 26 (21%) 33 (27%) 15 (12%)
Saline Week 13 9 (9%) 13 (13%) 14 (14%) 20 (20%) 26 (26%) 19 (19%)
Week 26 7 (7%) 15 (15%) 20 (20%) 13 (13%) 27 (27%) 19 (19%)
Overall assessment of treatment efﬁcacy as a function of time and treatment group. The patient was asked: ‘‘How would you rate the ef-
fectiveness of your osteoarthritis treatment right now?’’ Very good (1), good (2), satisfactory (3), adequate (4), poor (5), and unsatisfactory (6).
Data are for visits at weeks 13 and 26: ACS: N¼ 131; HA: N¼ 124; and NaCl: N¼ 101 (ITT population). The percentage of patients who were
at least satisﬁed with the treatment efﬁcacy was signiﬁcantly higher in the ACS group.
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‘‘Last visit minus baseline’’ statistical effects for efficacy variables at
weeks 7, 13 and 26 (ITT population)Of the 345 patients who participated in and completed the
initial study, 310 were traceable after 2 years (mean follow-
up time: 2.14 years, follow-up rate: w90%). Of these, 122
had received additional therapy (e.g., surgery, acupuncture,
subsequent medication on prescription, or another series of
intra-articular injections) for their study knee after the
6-month period and were thus re-evaluated separately us-
ing the LOCF method of imputation (Fig. 2a and b).
In both evaluations, all three groups still demonstrated
signiﬁcant improvements in OA symptoms as measured
by the WOMAC index and VAS. At the 2-year follow-up
evaluations, there were still statistically signiﬁcant differ-
ences between the ACS group and both control groups
with regard to WOMAC, VAS and GPA. The results demon-
strate that treatment with ACS results in a signiﬁcantly bet-
ter therapeutic effect compared to HA and saline not only at
6 months (double-blinded design), but also at 2 years (ob-
server-blinded design). Remarkably, the effects seen in pa-
tients who received HA or saline also persisted for the
additional 18 months.Variable P-value Comparison Signiﬁcance
WOMAC global <0.001 ACSesaline Yes
ACSeHA Yes
HAesaline No
WOMAC pain <0.001 ACSesaline Yes
ACSeHA Yes
HAesaline No
WOMAC stiffness <0.001 ACSesaline Yes
ACSeHA Yes
HAesaline No
WOMAC function <0.001 ACSesaline Yes
ACSeHA Yes
HAesaline No
VAS, response
(50% improvement)
ACS: 67%, HA: 32%,
saline: 33%
<0.001 ACSesaline Yes
ACSeHA Yes
HAesaline No
GPA, response
(score 3)
ACS: 70%, HA: 40%,
saline: 42%)
<0.001 ACSesaline Yes
ACSeHA Yes
HAesaline No
SF-8 PCS <0.001 ACSesaline Yes
ACSeHA Yes
HAesaline No
SF-8 MCS <0.001 ACSesaline Yes
ACSeHA Yes
HAesaline NoDiscussion
Our data show that ACS (Orthokine) is safe and has
a therapeutic effect on the major clinical parameters of pain-
ful knee OA. Remarkably, the therapeutic effect persists for
at least 2 years. The ACS production process has been
shown to reproducibly elevate IL-1Ra and other fac-
tors27,50,51, although the mechanisms by which the effects
are mediated are not fully understood. The multitude of syn-
ergistic, active therapeutic molecules may explain the ob-
served clinical effect, but its long-term persistence is more
difﬁcult to explain. One possibility may be that the therapeu-
tic molecules help to re-establish a healthy joint
homeostasis52.
The authors conclude that ACS is effective for treatment
of patients with low- to medium-grade, painful knee OA. We
treated only patients with a VAS pain score> 50/100 mm
(severe pain), so the results cannot necessarily be general-
ized to all OA patients.
Responder rates (patients with >50% pain reduction in
VAS pain score) were in the range of 71% after 3 months
and declined to 67% after 6 months. The mean improve-
ment for patients treated with HA or placebo was less
than half that in the ACS group (VAS). The differences com-
pared to the ACS group were statistically signiﬁcant from
week 7 through week 26 (P< 0.001). There were nosigniﬁcant differences between the HA treatment and pla-
cebo injections throughout the 26 weeks of the study
(P> 0.05).
These observations are in line with the well-recognized
signiﬁcant placebo response in patients with OA after either
aspiration of the knee synovial ﬂuid or injection with phar-
macologically non-active viscoelastic substances53e65.
However, the placebo group showed a longer beneﬁcial re-
sponse than expected based on the results of previous
studies with a similar design54,55,57,60.
The present study demonstrated highly similar treatment
effects for both HA and saline, despite an over 80% statis-
tical power to detect clinically relevant differences. It was
not the aim of this work to evaluate the effectiveness of
HA in OA. However, in the light of these clinical results,
we wish to comment that a number of publications and
meta-analyses have seriously questioned the effectiveness
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Table V
Percentage (and number) of patients with adverse events and
concomitant medication
ACS HA Saline
Overall incidence 23% (31)z 38% (51)y 28% (30)z
Mild 19% (25) 27% (37) 24% (26)
Moderate 4% (6) 7% (9) 2% (2)
Severe 0% (0) 5% (5) 2% (2)
Paracetamol/acetaminophen 17% (23) 26% (35) 31% (33)
Local adverse events as a function of treatment group. Antici-
pated adverse events were deﬁned as local reactions such as pres-
sure, transient knee pain, swelling, tenderness and heat at the
injection site. Patients with severe adverse events were treated
as withdrawals. Note that there is a statistically signiﬁcant differ-
ence in adverse effect occurrence between the HA group and the
ACS and saline groups (zP< 0.001 for the comparisons HAeACS
and HAesaline) and no differences between the ACS and the sa-
line group (yP> 0.05). Paracetamol, up to 4 g/day, was allowed
as rescue medication during the trial.
157Osteoarthritis and Cartilage Vol. 17, No. 2of HA in OA5,57,66e70 as well as the dependency of efﬁcacy
on the molecular mass of HA67,68,71,72.
NSAIDs give only modest control over the signs and
symptoms of OA. Scholes et al.73 found that only 15% of
patients with OA of the knee for whom a NSAID was pre-
scribed were still taking the same drug 12 months later. Cer-
tain cyclooxygenase-2 (COX-2) inhibitors have recently
been withdrawn as a result of cardiovascular complica-
tions7. The future of this class of drugs is now unclear. Their
claimed qualiﬁcation as OA medication may possibly be
due to what has been until now a lack of effective treatment
alternatives.
Although this study supports the use of ACS in mid-stage
painful OA of the knee, we are aware of its shortcomings.
The lower number of patients in the saline group may be ex-
plained by an initially asymmetric randomization process at
the external blood-processing site favoring the ACS and HA
groups. This problem was identiﬁed and corrected after in-
clusion of the ﬁrst 80 patients. The authors believe that,
given the strength of the clinical results, the informativeulation N = 188
60 72 84 96 108
 weeks
60 72 84 96 108
 weeks
ACS HA NaCl
opulation N = 310
ACS HA NaCl
roup 2 years after the last trial injections. (a) Valid-for-efﬁcacy-pop-
ical or surgical treatment for OA (ACS: N¼ 76; HA: N¼ 56; saline:
HA and saline; zP> 0.05 for the comparison HA vs saline. (b) In-
e carried forward in patients who received subsequent therapies.
HA and saline; zP> 0.05 for the comparison HA vs saline.
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Approximately 60% of subjects had undergone previous
knee surgery. The exclusion criteria eliminated subjects
who had undergone knee surgery within the previous 3
months, but earlier surgery could be a confounder in this
trial. However, there was no correlation between previous
surgery and treatment outcome. Interestingly, both cohorts
beneﬁted from the procedure. Analysis of the treatment
results showed that the non-surgically treated group experi-
enced the same statistically signiﬁcant changes as the total
study cohort. Another issue is the use of the Kellgrene
Lawrence score as an entry criterion. This score is quite in-
sensitive and prone to inter-observer error. Another problem
is that knees receiving HA and saline had three intra-
articular injections, while those receiving ACS had six.
This could not be avoided, because the manufacturer’s in-
structions for HA (Hyaject) require it to be given as a series
of three injections, and the ethics committee would not per-
mit six injections of saline. We do not know whether a higher
number of HA or saline injections would have altered the
outcome of the study. However, there is no unequivocal ev-
idence that a higher number of HA injections coincides with
better clinical results68,69,74e77. The number of ACS injec-
tions was deduced from clinical experience gathered since
2000. However, there is no conclusive data suggesting that
a lower number of ACS injections is clinically less effective.
Treatment in the aforementioned horse study was limited to
four injections of ACS or saline, and showed considerable
efﬁcacy in the ACS group28.
In a recently published ACS-Orthokine knee OA trial,
Yang et al.52 showed that ‘‘Autologous interleukin-1 recep-
tor antagonist improves function and symptoms in OA when
compared to placebo in a prospective randomized con-
trolled trial’’. Although their WOMAC data did not show an
effect as strong as that observed in the German Orthokine
Osteoarthritis Trial (GOAT), knee injury and osteoarthritis
outcome score (KOOS) and knee society clinical rating
scale (KSCRS) indicated signiﬁcant clinical superiority of
ACS over placebo. However, the two studies are only par-
tially comparable since the inclusion criteria (lower pain
scores at time of inclusion [VAS> 40 mm]), outcome instru-
ments, statistical methods and duration of observation were
different.
The demonstrated clinical improvement in a large number
of patients with painful OA treated with intra-articular ACS
containing elevated levels of autologous factors such as IL-
1Rasuggests that further investigation of the role of cytokines
in the pathogenesis of OA is merited. To this end, it would
have been instructive to measure the concentrations of key
cytokines in synovial ﬂuids aspirated from the study subjects.
Synovial IL-1Ra measurements in the horse study showed
qualitatively increasing IL-1Ra levels until day 71. However,
these assays were not performed in this study because the
protocol did not allow serial synovial ﬂuid aspiration.
In summary, intra-articular ACS (Orthokine) reduces pain
and increases function and mobility for up to 2 years, based
on double-blind 6-month results and observer-blinded 2-
year results. It can be considered as clinically very safe
because of its autologous origin. No clinically serious side
effects were observed in the ACS group during the observa-
tion period.
Conclusion
Intra-articular injection of ACS (Orthokine) in patients with
painful knee OA has an excellent safety proﬁle and results
in a strong clinical response. The data show that ACS(Orthokine) represents an effective and well-tolerated alter-
native to currently predominant treatments of OA. Further
investigation is necessary to determine whether these
effects are symptom-modifying or structure-modifying.
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